1604810-83-4

Basic information

• Product Name: THZ1
• Synonyms: THZ1;(E)-N-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide THZ1;N-[3-[[5-Chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-4-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]benzamide;(E)-N-(3-((5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-en;(E)-N-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide;THZ1 HY-80013 GTPL8052 SCHEMBL14979765;Benzamide, N-[3-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-4-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-
• CAS NO: 1604810-83-4
• Molecular Formula: C31H28ClN7O2
• Molecular Weight: 566.07
• Product Categories: API
• Mol File: 1604810-83-4.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.379±0.06 g/cm3(Predicted)
• Solubility: ≥28.3 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
• PKA: 12.94±0.70(Predicted)
• CAS DataBase Reference: THZ1(CAS DataBase Reference)
• NIST Chemistry Reference: THZ1(1604810-83-4)
• EPA Substance Registry System: THZ1(1604810-83-4)

Safety Data

• Hazardous Substances Data: 1604810-83-4(Hazardous Substances Data)

Usage

Description

THZ1 is a covalent cyclin-dependent kinases 7 (CDK7) inhibitor that selectively targets a remote cysteine residue located outside of the canonical kinase domain, making it a promising compound for various applications.

Uses

Used in Pharmaceutical Industry:
THZ1 is used as a CDK7 inhibitor for its ability to selectively target CDK7, which plays a crucial role in the regulation of cell cycle progression and transcription. This selective targeting provides a potential therapeutic approach for the treatment of various diseases, including cancer, where CDK7 is often dysregulated.
Used in Cancer Research:
THZ1 is used as a research tool for studying the role of CDK7 in cancer cell proliferation and survival. Its selective inhibition of CDK7 can help researchers understand the underlying mechanisms of cancer development and identify potential therapeutic targets for cancer treatment.
Used in Drug Development:
THZ1 is used as a lead compound in the development of novel therapeutics for cancer treatment. Its unique mechanism of action and selectivity for CDK7 make it an attractive candidate for further optimization and development into a more potent and selective CDK7 inhibitor with improved pharmacological properties.
Used in Drug Delivery Systems:
THZ1 can be used as an active pharmaceutical ingredient in the development of drug delivery systems designed to improve its bioavailability, delivery, and therapeutic outcomes. These systems may include nanoparticles, liposomes, or other advanced drug delivery technologies to enhance the efficacy and safety of THZ1 in treating diseases, particularly cancer.

Biological Activity

thz1 is a covalent inhibitor of cdk7 with ic50 value of 3.2nm [1].thz1 covalently modifies cdk7 by targeting c312 residue outside of the kinase domain, providing an unanticipated means of achieving covalent selectivity. thz1 potently inhibits proliferation of jurkat and loucy t-all cell lines with ic50 values of 50nm and 0.55nm, respectively. in the kinase binding assay, thz1 shows a good binding affinity with ic50 value of 3.2nm [1].as an inhibitor of cdk7, thz1 inhibits the phosphorylation of the c-terminal domain of rnap polymerase ii, effecting the regulation of transcription. thz1 also inhibits the activation of the cdk proteins. it is reported to disrupt the cdk7 signalling pathways both in jurkat cells and loucy cells. thz1 shows a broad-based activity with ic50 values less than 200nm in a variety of cancer cell lines. among these cell lines, t-all is exceptional sensitivity to thz1 due to the transcription effect of runx1 caused by thz1 [1].

references

[1] nicholas kwiatkowski, tinghu zhang, peter b. rahl et al. targeting transcription regulation in cancer with a covalent cdk7 inhibitor. nature, 2014.